Navigation Links
Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
Date:3/28/2011

BASKING RIDGE, N.J., March 28, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that Thomas J. Povsic, MD, PhD, Assistant Professor of Medicine at Duke University, will present results of the RADAR Phase 2b clinical trial for the Company's lead product, the REG1 anticoagulation system, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo.

The presentation, "A Randomized, Partially-Blinded, Multi-Center, Active-Controlled, Dose-ranging Study Assessing the Safety, Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Weight Heparin in Subjects with Acute Coronary Syndromes: Primary Results of the RADAR Randomized Clinical Trial," will be given during an i2 Special Session entitled: "Interventional Featured Clinical Studies I" on Sunday, April 3, 2011 at 1:15 p.m. CDT at the Ernest N. Morial Convention Center in New Orleans, LA.

REG1 comprises a two-component system; a highly selective Factor IXa inhibiting aptamer, pegnivacogin, and its complementary specific active control agent, anivamersen.  Anivamersen can be used to selectively reverse (completely or partially) the anticoagulant effect of pegnivacogin in real time.

ABOUT REGADO BIOSCIENCES

Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent.  This technology is being applied to injectable antithrombotics (including antico
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
2. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
3. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
4. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
5. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
6. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
7. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
8. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
9. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
10. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
11. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... TAMPA, Fla. , Sept. 17, 2014   ... announced today that Business Insurance magazine has ... Insurance" distinction for the third year in a row. ... joint effort of Business Insurance  and the Best ... evaluation, is open to all publicly or privately-held insurance ...
(Date:9/17/2014)... , Sept. 17, 2014 Women everywhere know ... are not only uncomfortable, they,re often also embarrassing and ... pH-D Feminine Health Support ( http://ph-defense.com ) is a ... is an all-natural, homeopathic product. Odor, ... symptoms of vaginal infection. In many cases, the cause ...
(Date:9/17/2014)... 2014  NuView Life Sciences, Inc. (NuView) announced ... agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) to ... biomarker to detect cancers of the breast and ... diagnostic-imaging applications. NuView retains all rights for the ... urine screen applications. Under the terms ...
Breaking Medicine Technology:myMatrixx Honored with "Best Places to Work in Insurance" Award 2New Product from Vireo Systems: pH-D Feminine Health Support 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5
... that a new market research report is available ... Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th ... DescriptionThe report provides a detailed understand ... co-promotion and co-marketing deals. The majority of deals ...
... Oct. 7 CryoLife, Inc. (NYSE: CRY ... processing company, today announced that its BioGlue Surgical Adhesive ... Health, Labor and Welfare (MHLW) for use in the ... Medical, Inc. (CMI) will distribute BioGlue in Japan for ...
Cached Medicine Technology:Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition 2Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition 3Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition 4Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition 5Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition 6Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition 7Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition 8Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition 9CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 2CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 3CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 4CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 5
(Date:9/17/2014)... Dennis Thompson ... News) -- Exposure in the womb to household chemicals ... of developing asthma, Columbia University researchers reported in a ... increased risk of developing asthma between age 5 and ... high levels of two phthalates (pronounced thal-ates), the researchers ...
(Date:9/17/2014)... -- Positive messages about the health benefits of quitting ... new study suggests. Although smokers who think quitting ... the harmful effects of smoking, researchers found smokers who ... from "gain-framed," or positive, messages about how quitting will ... a mix of both types of messages might get ...
(Date:9/17/2014)... adjourns this month for the November elections, one of ... way out the chamber door will be the Sustainable ... Act of 2014. In a new commentary in the ... what he and other advocates saw as the merits ... how Medicare pays doctors will return for the next ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Wright ... Conserve line of metal-on-metal hip replacements continue to ... U.S. District Court, Northern District of Georgia, Bernstein ... List issued by the U.S. Judicial Panel on ... 397 product liability claims have been filed in ...
(Date:9/17/2014)... 17, 2014 Boston Children’s Museum ... a monthly concert series, introducing young Museum visitors ... Top, America’s premier national platform celebrating the stories, ... of the young musicians featured will also be ... Children’s Museum is fortunate to partner with the ...
Breaking Medicine News(10 mins):Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:Failed Medicare payments law remains relevant 2Health News:Failed Medicare payments law remains relevant 3Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3
... LANSDOWNE, Va., Oct. 8 The Care Net Board ... of the,organization, will follow Kurt Entsminger as interim President ... for a new leader. Entsminger, who,announced his resignation last ... Counsel and then as President since 2003., "The ...
... Campaign to Educate, Support, Raise Funds for Research, ... form of lupus, the chronic (incurable) disease that can,result ... skin,rashes, anemia, chest pains, sun sensitivity, and other health ... of,childbearing age -- between 15 and 44 -- although ...
... Radlink, Inc., a supplier,of affordable medical imaging ... practices, today named Allan Christensen vice,president of Technical ... developing technical services and processes for the company,s ... and supporting the,direct and indirect sales channels. ...
... The Integrated Healthcare,Association (IHA) presented top performance ... (SRMG), affiliated with Sutter Regional,Medical Foundation (SRMF), ... (P4P),Stakeholders Meeting last week. SRMG was ... important,health care quality measures, including preventive care ...
... Capital Investments,Inc. (Amex: MGT ), a holding company ... that the Company,s Chairman and,CEO, Tim Paterson-Brown, has acquired ... in a single private transaction at $3.75 per,share, for ... has been my belief,for some time now that the ...
... Repair and Rejuvenate When Nutrition Matters Most, MINNEAPOLIS, ... and loss of appetite are some of the many ... Whether,you,re fighting the battle or caring for someone who ... road to recovery. "One of the most important ...
Cached Medicine News:Health News:Care Net Announces New Leadership: Melinda Delahoyde to Follow Kurt Entsminger as President 2Health News:October is Lupus Awareness Month 2Health News:October is Lupus Awareness Month 3Health News:Radlink Names Allan Christensen Vice President of Technical Services 2Health News:Solano Regional Medical Group and Sutter Regional Medical Foundation Recognized by Integrated Healthcare Association (IHA) 2Health News:MGT Chairman and CEO Buys 250,000 MGT shares 2Health News:Proven Nutrition Provides Energy and Hope to Cancer Fighters 2Health News:Proven Nutrition Provides Energy and Hope to Cancer Fighters 3
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: